Drug Trial Radar · NCT02251275
Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
Last checked: Nov 20, 2026Latest source record: Nov 27, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,803
Actual
Start
Oct 17, 2014
Primary completion
Nov 9, 2018
Study completion Nov 9, 2018
Sponsor
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
- Sponsor type
- Industry
- First posted
- Sep 29, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the trial was to evaluate and describe the long term safety of tolvaptan in participants with autosomal dominant polycystic kidney disease (ADPKD).
Conditions
- Polycystic Kidney, Autosomal Dominant
Interventions
TolvaptanDrug
Tolvaptan tablets (15 or 30 mg) self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number Of Participants Reporting Treatment-Emergent Adverse Events (TEAEs)Time frame: Baseline through end of treatment (up to 42 months) and follow-up 7 days posttreatment(+ 7 days)
Locations
210 sites in 20 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Huntsville, Alabama
Site not named
Mobile, Alabama
Site not named
Phoenix, Arizona
Site not named
Tempe, Arizona
Site not named
Tucson, Arizona
Site not named
La Jolla, California
Site not named
Los Angeles, California
Site not named
Los Angeles, California
Site not named
San Francisco, California
Site not named
Stanford, California
Site not named
Aurora, Colorado
Site not named
Denver, Colorado
Site not named
Denver, Colorado
Site not named
New Haven, Connecticut
Site not named
Hudson, Florida
Site not named
Jacksonville, Florida
Site not named
Miami, Florida
Site not named
Ocala, Florida
Site not named
Port Charlotte, Florida
Site not named
Tampa, Florida
Site not named
Atlanta, Georgia
Site not named
Augusta, Georgia
Site not named
Meridian, Idaho
Site not named
Chicago, Illinois
Site not named
Chicago, Illinois
Site not named
Kansas City, Kansas
Site not named
Wichita, Kansas
Site not named
Baton Rouge, Louisiana
Site not named
Baltimore, Maryland
Site not named
Baltimore, Maryland
Site not named
Greenbelt, Maryland
Site not named
Rockville, Maryland
Site not named
Boston, Massachusetts
Site not named
Springfield, Massachusetts
Site not named
Detroit, Michigan
Site not named
Grand Rapids, Michigan
Site not named
Kalamazoo, Michigan
Site not named
Pontiac, Michigan
Site not named
Roseville, Michigan
Showing 40 of 210 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.